Cost-consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS

about

Cost-consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS

Item

http://www.wikidata.org/entity/Q58763035

description

article

@en

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Cost-consequence analysis of f ...... ent of COPD in the Spanish NHS

@en

Cost-consequence analysis of f ...... ent of COPD in the Spanish NHS

@nl

type

Item

label

Cost-consequence analysis of f ...... ent of COPD in the Spanish NHS

@en

Cost-consequence analysis of f ...... ent of COPD in the Spanish NHS

@nl

prefLabel

Cost-consequence analysis of f ...... ent of COPD in the Spanish NHS

@en

Cost-consequence analysis of f ...... ent of COPD in the Spanish NHS

@nl

P1476

Cost-consequence analysis of f ...... ent of COPD in the Spanish NHS

@en

P2093

Alicia Gil

http://www.w3.org/2001/XMLSchema#string

Alicia Huerta Hernandez

http://www.w3.org/2001/XMLSchema#string

Germán Peces-Barba

http://www.w3.org/2001/XMLSchema#string

Laura Amanda Vallejo-Aparicio

http://www.w3.org/2001/XMLSchema#string

P2860

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

Study of the burden on patients with chronic obstructive pulmonary disease.

Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease.

Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study.

Costs of chronic bronchitis and COPD: a 1-year follow-up study.

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

[Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study]

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement

Diferencias geográficas en la prevalencia de EPOC en España: relación con hábito tabáquico, tasas de mortalidad y otros determinantes

P304

501-510

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CEOR.S169154

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30233222

http://www.w3.org/2001/XMLSchema#string

P921

health policy

P932

6132231

http://www.w3.org/2001/XMLSchema#string